{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:26:16Z","timestamp":1792524376365,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.berh.2011.10.004","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T14:17:33Z","timestamp":1323353853000},"page":"549-567","source":"Crossref","is-referenced-by-count":116,"title":["Anti-TNF therapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Nishanthi","family":"Thalayasingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacology & Therapeutics"},{"issue":"8","key":"10.1016\/j.berh.2011.10.004_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780310816","article-title":"Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum","volume":"31","author":"Saxne","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"13","key":"10.1016\/j.berh.2011.10.004_bib3","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"The EMBO Journal"},{"issue":"12","key":"10.1016\/j.berh.2011.10.004_bib4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cytogfr.2004.03.011","article-title":"Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system","volume":"15","author":"Eissner","year":"2004","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"3","key":"10.1016\/j.berh.2011.10.004_bib6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coph.2010.01.005","article-title":"Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases","volume":"10","author":"Taylor","year":"2010","journal-title":"Current Opinion in Pharmacology"},{"issue":"9194","key":"10.1016\/j.berh.2011.10.004_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2011.10.004_bib8","unstructured":"Merck, Sharp, Dohme Ltd. Remicade, summary of product characteristics. 2011."},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.10.004_bib11","unstructured":"Abbott Laboratories Ltd. Humira, summary of product characteristics. 2011."},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2011.10.004_bib13","unstructured":"Wyeth Pharmaceuticals. Enbrel, summary of product characteristics. 2011."},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.30263","article-title":"The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy","volume":"63","author":"Emery","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.10.004_bib16","unstructured":"Merck, Sharp, Dohme Ltd. Simponi, summary of product characteristics. 2011."},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/rheumatology\/keq285","article-title":"Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety","volume":"50","author":"Mease","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.berh.2011.10.004_bib18","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.10.004_bib21","unstructured":"UCB Pharma Ltd. Cimzia, summary of product characteristics. 2011."},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMp1107285","article-title":"Developing the nation\u2019s biosimilars program","volume":"365","author":"Kozlowski","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2011.10.004_bib23","series-title":"European medicines agency guideline on similar biological medicinal products","author":"CHMP","year":"2005"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.10.004_bib24","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndtplus\/sfn177","article-title":"Biosimilar therapeutics-what do we need to consider?","volume":"2","author":"Schellekens","year":"2009","journal-title":"NDT Plus"},{"issue":"9410","key":"10.1016\/j.berh.2011.10.004_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Soliman","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1016\/j.berh.2011.10.004_bib28","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.berh.2011.10.004_bib29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis","volume":"352","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib32","doi-asserted-by":"crossref","DOI":"10.1378\/chest.128.2.1062","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib34","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.180.2.688","article-title":"Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks","volume":"180","author":"Anolik","year":"2008","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cyto.2004.06.008","article-title":"Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes","volume":"28","author":"Kirchner","year":"2004","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.berh.2011.10.004_bib37","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in\u00a0vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib38","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/ard.2010.141549","article-title":"Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab","volume":"70","author":"Herenius","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"14","key":"10.1016\/j.berh.2011.10.004_bib39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0161-5890(02)00036-6","article-title":"Recognition of immunoglobulins by Fcgamma receptors","volume":"38","author":"Radaev","year":"2002","journal-title":"Molecular Immunology"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2011.10.004_bib41","first-page":"136","article-title":"Murine model for assessing adalimumab, infliximab and etanercept to prevent polyarthritis","volume":"62","author":"Kaymakcalan","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1\u20132","key":"10.1016\/j.berh.2011.10.004_bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jim.2009.06.009","article-title":"Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis","volume":"348","author":"Palframan","year":"2009","journal-title":"Journal of Immunological Methods"},{"issue":"9","key":"10.1016\/j.berh.2011.10.004_bib43","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1073\/pnas.1011774108","article-title":"Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system","volume":"108","author":"Hess","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/ard.2009.108035","article-title":"Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)","volume":"69","author":"Augustsson","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1016\/j.berh.2011.10.004_bib45","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1136\/ard.2009.127852","article-title":"Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study","volume":"69","author":"Olofsson","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1016\/j.berh.2011.10.004_bib46","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.10.004_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"14","key":"10.1016\/j.berh.2011.10.004_bib48","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA: the Journal of the American Medical Association"},{"issue":"8","key":"10.1016\/j.berh.2011.10.004_bib49","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jbspin.2010.02.021","article-title":"Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients","volume":"77","author":"Finckh","year":"2010","journal-title":"Joint, Bone, Spine: Revue du Rhumatisme"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib51","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/art.30209","article-title":"Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study","volume":"63","author":"Korswagen","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.10.004_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2011.153536","article-title":"Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","author":"Davies","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1016\/j.berh.2011.10.004_bib53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib54","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.10.004_bib55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study","volume":"66","author":"Furst","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","article-title":"Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study","volume":"65","author":"Nikas","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"9685","key":"10.1016\/j.berh.2011.10.004_bib58","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Karlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.berh.2011.10.004_bib60","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/rheumatology\/kel054","article-title":"Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody","volume":"45","author":"Solau-Gervais","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2011.10.004_bib61","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib63","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","article-title":"B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents","volume":"56","author":"Finckh","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib65","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.10.004_bib67","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib68","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib69","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib70","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.berh.2011.10.004_bib71","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Pallavicini","year":"2010","journal-title":"Autoimmunity Reviews"},{"issue":"10","key":"10.1016\/j.berh.2011.10.004_bib72","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib73","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Research & Therapy"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.10.004_bib75","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.30247","article-title":"Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents","volume":"63","author":"Raaschou","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1016\/j.berh.2011.10.004_bib76","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care & Research"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nature Reviews Cancer"},{"issue":"8","key":"10.1016\/j.berh.2011.10.004_bib78","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.berh.2011.10.004_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2011.152769","article-title":"Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","author":"Galloway","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1016\/j.berh.2011.10.004_bib80","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.berh.2011.10.004_bib82","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.10.004_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","author":"Strangfeld","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib84","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib85","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib86","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2011.10.004_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis","author":"van Sijl","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib88","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis","volume":"60","author":"van Eijk","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1016\/j.berh.2011.10.004_bib89","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.berh.2011.10.004_bib90","first-page":"1213","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2011.10.004_bib91","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/ard.2006.062497","article-title":"Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis","volume":"66","author":"Jacobsson","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1016\/j.berh.2011.10.004_bib92","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/art.27660","article-title":"No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Lunt","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.berh.2011.10.004_bib93","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib94","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ard.2010.135376","article-title":"The need for personalised medicine for rheumatoid arthritis","volume":"70","author":"Isaacs","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1016\/j.berh.2011.10.004_bib95","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/ken002","article-title":"Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Kristensen","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2011.10.004_bib96","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2011.10.004_bib97","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1016\/j.berh.2011.10.004_bib98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1016\/j.berh.2011.10.004_bib99","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2011.10.004_bib100","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","article-title":"The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study","volume":"50","author":"Klaasen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.berh.2011.10.004_bib101","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar2706","article-title":"Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis","volume":"11","author":"Hueber","year":"2009","journal-title":"Arthritis Research & Therapy"},{"issue":"3","key":"10.1016\/j.berh.2011.10.004_bib102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/clpt.2009.244","article-title":"CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis","volume":"87","author":"Stuhlmuller","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694211000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694211000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T12:21:10Z","timestamp":1561033270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694211000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S1521694211000799"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2011.10.004","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}